CAMBRIDGE, Mass. - s4story -- Highland Instruments today announced that it has been awarded a $4 million Commercialization Readiness Program (CRP) grant from the National Institutes of Health (NIH). This funding will support late-stage research and development (R&D) activities to prepare ESStim™, Highland's novel noninvasive brain stimulation platform, for commercialization.

Highland Instruments has completed 13 clinical studies of more than 400 patients, investigating ESStim™'s safety and effectiveness across six indications in the fields of addiction, chronic pain, and movement disorders. The CRP grant, an extension of Highland's previous research on ESStim™ for treating chronic lower back pain, will enable Highland to complete late-stage R&D activities to prepare ESStim™ for commercialization, including final aesthetic design, human factors testing, and validation for manufacturing at scale.

More on S For Story

• From the U.S. Marines to the Cosmos: Texas Veteran Elevates "Beyond Odyssey" Universe to Carry NASA's Spirit of Exploration Into Tomorrow
• TradingHabits.com Launches to Support Day Trader Well-being
• $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
• $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
• BITE Data raises $3m to build AI tools for global trade compliance teams

"This CRP grant is an important milestone for our company, and for the millions of patients that could benefit from ESStim™" said Tim Wagner, PhD, Founder and Chief Scientific Officer of Highland Instruments. "The grant will enable us to take the critical next steps toward commercializing ESStim™."

ESStim™ has the potential to advance care for almost 70 million Americans. These patients typically face treatment choices between medications, which can wane in effectiveness, and surgical procedures, which are costly and invasive. ESStim™ will potentially offer patients a new option – noninvasive brain stimulation – to address these conditions.

"ESStim™ has established a strong scientific foundation in clinical studies," added Laura Dipietro, PhD, Highland's Chief Technology Officer. "This funding will support our efforts to incorporate clinician insights and patient feedback to optimize ESStim™ as a clinically robust and user-friendly device ready for commercial launch."

More on S For Story

• Phinge Issues Notice of Possible Infringement, Investigates App-less AI Agents & Technology for Unauthorized Use of its Patented App-less Technologies
• Huntington Learning Center of Russellville Marks 1 Year Anniversary; Extends Reduced Grant-Aligned Rates to All Students in Learning Center Services
• CCHR Supports Call to End Coercive Psychiatry at World Mental Health Congress
• purelyIV Expands Wellness Services with Flu/COVID Testing and Menopause Coaching & Treatment
• George Simon Laso Releases New Book - The Art of Confusion

***

About Highland Instruments
Highland Instruments is a neurotechnology company innovating ESStim™, a novel brain stimulation platform to help patients address addiction, chronic pain, and movement disorders. Learn more at www.highlandinstruments.com.

ESStim™ has not been approved by the Food and Drug Administration for a specific clinical indication. This technology is not in commercial distribution in the United States or internationally. Please contact Highland Instruments for additional information regarding this technology and potential clinical application.

This grant will be provided by the National Institute on Aging, one of the 27 centers of the NIH, under Award Number SB1AG091887. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.